Case number 2017-1480
Amgen Inc. v. Sanofi > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | AMGEN INC. v. SANOFI [OPINION] [precedential] (0) |
| Jan 7, 2019 | 182 | The petition for writ of certiorari, [18-127], filed on 07/23/2018, was Denied on 01/07/2019. [576526] [JAB] [Entered: 01/08/2019 08:06 AM] (1) |
| Jul 30, 2018 | 181 | Petition for writ of Certiorari filed on 07/23/2018, and placed on the docket 07/27/2018, in the Supreme Court of the United States. Supreme Court #: 18-127, Amgen Inc., et al. v. Sanofi, et al. [539428] [JAB] [Entered: 07/30/2018 02:45 PM] (1) |
| May 21, 2018 | 180 | Notice from the Supreme Court of the United States: The application for an extension of time within which to file a petition for a writ of certiorari in the above-entitled case has been presented to the Chief Justice, who on May 14, 2018, extended the time to and including July 23,2018. [524114] [SJ] [Entered: 05/24/2018 08:18 AM] (3) |
| Mar 2, 2018 | 179 | Mandate issued to the United States District Court for the District of Delaware. Service as of this date by the Clerk of Court. [502271] [JAB] [Entered: 03/02/2018 09:40 AM] (1) |
| Feb 23, 2018 | 178 | ORDER filed denying [163] petition for en banc rehearing filed by Amgen Manufacturing Limited, Amgen USA, Inc. and Amgen Inc. By: En Banc (Per Curiam). Service as of this date by the Clerk of Court. [500618] [SJ] [Entered: 02/23/2018 10:46 AM] (2) |
| Feb 8, 2018 | 177 | 18 paper copies of the response [176] received from Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. [496395] [SJ] [Entered: 02/08/2018 03:02 PM] (0) |
| Feb 6, 2018 | 176 | RESPONSE of Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC to the petition for en banc rehearing [163] filed by Appellees Amgen Manufacturing Limited, Amgen USA, Inc. and Amgen Inc. in 17-1480. Service: 02/06/2018 by email. [495706] [Paul Clement] [Entered: 02/06/2018 05:04 PM] (27) |
| Jan 19, 2018 | 175 | ORDER filed granting motion to extend time to file a response to en banc/rehearing petition [174] filed by Appellants Sanofi-Aventis U.S., LLC, Sanofi, Aventisub LLC and Regeneron Pharmaceuticals Inc.. By: (Per Curiam). Service as of this date by Clerk of Court. [490840] [SJ] [Entered: 01/19/2018 08:44 AM] (2) |
| Jan 9, 2018 | 173 | The court invites a response from Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC to the petition for en banc rehearing filed by Appellees in 17-1480. [488351] [SJ] [Entered: 01/09/2018 02:12 PM] (1) |
| Jan 9, 2018 | 174 | MOTION of Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC to extend the time to file a response to the Petition for Rehearing En Banc until 02/06/2018 at 11:00 pm. Any response is due within 10 days of service [Consent: unopposed]. Service: 01/09/2018 by email. [488522] [Paul Clement] [Entered: 01/09/2018 10:12 PM] (7) |
| Dec 28, 2017 | 172 | 18 paper copies of the amicus Brief [171] received from Amici Curiae Bavarian Nordic A/S, Bristol-Myers Squibb Company and Enzo Biochem, Inc. [485984] [JAB] [Entered: 12/28/2017 10:20 AM] (0) |
| Dec 26, 2017 | 170 | ORDER filed granting motion to file amicus brief on en banc or rehearing petition [168]. By: Merits Panel (Per Curiam). Service as of this date by Clerk of Court. [485533] [JAB] [Entered: 12/26/2017 01:20 PM] (2) |
| Dec 26, 2017 | 171 | AMICUS BRIEF FILED on Petition for Bavarian Nordic A/S, Bristol-Myers Squibb Company and Enzo Biochem, Inc. [169]. Pages: 14. The filer is directed to submit the approriate number of copies within two days, see Fed. Cir. R. 25(c). [485537] [JAB] [Entered: 12/26/2017 01:25 PM] (27) |
| Dec 20, 2017 | 165 | Entry of appearance for Eldora L. Ellison as of counsel for Bavarian Nordic A/S, Bristol-Myers Squibb Company, Enzo Biochem, Inc.. Service: 12/20/2017 by email. [484501] [Eldora Ellison] [Entered: 12/20/2017 05:56 PM] (2) |
| Dec 20, 2017 | 166 | Entry of appearance for Jon E. Wright as of counsel for Bavarian Nordic A/S, Bristol-Myers Squibb Company, Enzo Biochem, Inc.. Service: 12/20/2017 by email. [484504] [Jon Wright] [Entered: 12/20/2017 05:58 PM] (2) |
| Dec 20, 2017 | 167 | Entry of appearance for Jorge A. Goldstein as principal counsel for Bavarian Nordic A/S, Bristol-Myers Squibb Company, Enzo Biochem, Inc.. Service: 12/20/2017 by email. [484506] [Jorge Goldstein] [Entered: 12/20/2017 06:00 PM] (2) |
| Dec 20, 2017 | 168 | MOTION of Bavarian Nordic A/S, Bristol-Myers Squibb Company, Enzo Biochem, Inc. for leave to file amicus brief in support of AMGEN INC., AMGEN MANUFACTURING LIMITED, AMGEN USA, INC., on petition for en banc rehearing [163]. Any response is due within 10 days of service [Consent: unopposed]. Service: 12/20/2017 by email. [484511] [Jorge Goldstein] [Entered: 12/20/2017 06:07 PM] (12) |
| Dec 20, 2017 | 169 | TENDERED from Bavarian Nordic A/S, Bristol-Myers Squibb Company, Enzo Biochem, Inc. Title: AMICUS CURIAE BRIEF. Service: 12/20/2017 by email. [484517] [Jorge Goldstein] [Entered: 12/20/2017 06:11 PM] (27) |
| Dec 11, 2017 | 164 | 18 paper copies of the petition for en banc rehearing [163] received from Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc. [481667] [SJ] [Entered: 12/11/2017 03:26 PM] (0) |
| Dec 6, 2017 | 163 | Petition for en banc rehearing filed by Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 12/06/2017 by email. The paper copies of the petition must be filed within two business days (see Fed. Cir. R. 35(c)(4).The required paper copies should be received by the court on or before 12/08/2017 [480779] [Daryl Joseffer] [Entered: 12/06/2017 04:40 PM] (55) |
| Nov 1, 2017 | 161 | ORDER filed granting motion to extend time to file petition for rehearing [159] filed by Appellees Amgen Manufacturing Limited, Amgen USA, Inc. and Amgen Inc. Petition for Rehearing due on or before 12/06/2017. By: Merits Panel (Per Curiam). Service as of this date by Clerk of Court. [472109] [SJ] [Entered: 11/01/2017 08:55 AM] (2) |
| Nov 1, 2017 | 162 | Entry of appearance for Jeffrey A. Lamken as of counsel for Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 11/01/2017 by email. [472347] [Jeffrey Lamken] [Entered: 11/01/2017 03:51 PM] (2) |
| Oct 27, 2017 | 159 | MOTION of Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc. to extend the time to file a Combined Petition for Panel Rehearing and Rehearing En Banc until 12/06/2017 at 11:59 pm. [Consent: opposed]. Service: 10/27/2017 by email. [471101] [Daryl Joseffer] [Entered: 10/27/2017 01:25 PM] (9) |
| Oct 27, 2017 | 160 | RESPONSE of Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC to the motion to extend time to file petition for rehearing [159] filed by Appellees Amgen Manufacturing Limited, Amgen USA, Inc. and Amgen Inc. in 17-1480. Service: 10/27/2017 by email. [471123] [Paul Clement] [Entered: 10/27/2017 02:51 PM] (6) |
| Oct 5, 2017 | 158 | OPINION and JUDGMENT filed. The judgment or decision is: Reversed in Part, Affirmed in Part, Vacated in Part, and Remanded. (Precedential Opinion). (For the Court: Prost,Chief Judge; Taranto,Circuit Judge and Hughes,Circuit Judge). [465756] [SJ] [Entered: 10/05/2017 09:48 AM] (28) |
| Sep 1, 2017 | 156 | MOTION of Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC to withdraw counsel Christopher G. Michel. Any response is due within 10 days of service [Consent: not addressed]. Service: 09/01/2017 by email. [458266] [Christopher Michel] [Entered: 09/01/2017 11:54 AM] (6) |
| Sep 1, 2017 | 157 | **TEXT ONLY** ORDER granting motion to withdraw attorney Christopher G. Michel [156] filed by Appellants Sanofi-Aventis U.S., LLC, Sanofi, Aventisub LLC and Regeneron Pharmaceuticals Inc. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [458302] [JAB] [Entered: 09/01/2017 12:42 PM] (0) |
| Jun 6, 2017 | 155 | Submitted after ORAL ARGUMENT by Paul D. Clement for Sanofi-Aventis U.S., LLC, Sanofi, Aventisub LLC and Regeneron Pharmaceuticals Inc. and Daryl Joseffer for Amgen Manufacturing Limited, Amgen USA, Inc. and Amgen Inc. Panel: Judge: Prost , Judge: Taranto , Judge: Hughes. [436752] [SJ] [Entered: 06/06/2017 02:28 PM] (0) |
| May 22, 2017 | 154 | Notice from Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc. Visual Aids at Oral Argument. Service: 05/22/2017 by email. [433258] [Daryl Joseffer] [Entered: 05/22/2017 03:55 PM] (2) |
| May 8, 2017 | 153 | Clerk's Note to the File: Oral argument in this case will be heard in Courtroom 402, rather than Courtroom 201. [429751] [JAB] [Entered: 05/08/2017 03:54 PM] (0) |
| May 5, 2017 | 152 | RESPONSE of Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc. to the supplemental authority [151] filed by Appellants Sanofi-Aventis U.S., LLC, Sanofi, Aventisub LLC and Regeneron Pharmaceuticals Inc. in 17-1480. Service: 05/05/2017 by email. [429535] [Daryl Joseffer] [Entered: 05/05/2017 08:56 PM] (3) |
| May 3, 2017 | 151 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Service: 05/03/2017 by email. [428801] [Paul Clement] [Entered: 05/03/2017 12:27 PM] (29) |
| May 2, 2017 | 150 | Response to oral argument order from the Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. designating Paul D. Clement as arguing attorney. Designated time for argument: 12 minutes. Designated time for rebuttal: 3 minutes. Service of other counsel by Notice of Docket Activity from this entry. [428401] [Paul Clement] [Entered: 05/02/2017 09:47 AM] (0) |
| Apr 24, 2017 | 149 | Response to oral argument order from the Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. designating Daryl L. Joseffer as arguing attorney. Designated time for argument: 15 minutes. Designated time for rebuttal: 0 minutes. Service of other counsel by Notice of Docket Activity from this entry. [426535] [Daryl Joseffer] [Entered: 04/24/2017 11:40 AM] (0) |
| Apr 21, 2017 | 148 | NOTICE OF CALENDARING. Panel: 1706D. Case scheduled Jun 06, 2017 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, N.W. Washington, DC 20439), Courtroom 201. Response to oral argument order due: 05/15/2017. Arguing counsel is required to check-in at the Clerk's Office, 4th Floor, Room 401, between 8:30 am and 9:30 am on the day of argument. Please review the Oral Argument Order. [426268] [JAB] [Entered: 04/21/2017 03:10 PM] (0) |
| Apr 19, 2017 | 147 | Notice from Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC regarding conflicts with oral argument (May 4-5, 8-12, 15-19, 22-26, 29, 31; June 1-2, 5, 9, 12-16, 19-23; July 10- 14; and August 21-23.). Service: 04/19/2017 by email. [425600] [Paul Clement] [Entered: 04/19/2017 02:57 PM] (1) |
| Apr 14, 2017 | 146 | 6 paper copies of the Confidential Joint Appendix (Vol. I-VI) [140] received from Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. [424278] [KW] [Entered: 04/14/2017 02:16 PM] (0) |
| Apr 13, 2017 | 145 | Statement of Compliance with Fed. Cir. R. 33 for Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi, Sanofi-Aventis U.S., LLC and Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 04/13/2017 by email. [423756] [Paul Clement] [Entered: 04/13/2017 10:29 AM] (4) |
| Apr 10, 2017 | 142 | Notice to counsel: The record of this case indicates that the Certificate of Compliance with Fed. Cir. R. 11(d) has not been filed. IF any portion of the record in the trial court/agency is subject to a protective order, counsel should promptly file the appropriate Certificate of Compliance using the Cert of Compliance Modification of Protective Order (R11/17) event which is found in the Forms and Certificates category. Service as of this date by Clerk of Court. [422836] [JCA] [Entered: 04/10/2017 02:50 PM] (0) |
| Apr 10, 2017 | 143 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Service: 04/10/2017 by email. [422907] [Paul Clement] [Entered: 04/10/2017 04:20 PM] (3) |
| Apr 10, 2017 | 144 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 04/10/2017 by email. [422934] [Daryl Joseffer] [Entered: 04/10/2017 05:05 PM] (3) |
| Apr 7, 2017 | 136 | Letter from Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc. Scheduling of Oral Argument. Service: 04/07/2017 by email. [422468] [Daryl Joseffer] [Entered: 04/07/2017 03:07 PM] (2) |
| Apr 7, 2017 | 137 | TENDERED from Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Title: CONFIDENTIAL JOINT APPENDIX Service: 04/07/2017 by email. [422579] [Paul Clement] [Entered: 04/07/2017 09:38 PM] (0) |
| Apr 7, 2017 | 138 | TENDERED from Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Title: CONFIDENTIAL JOINT APPENDIX Service: 04/07/2017 by email. [422580] [Paul Clement] [Entered: 04/07/2017 09:42 PM] (0) |
| Apr 7, 2017 | 139 | TENDERED from Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Title: JOINT APPENDIX. Service: 04/07/2017 by email. [422581] [Paul Clement] [Entered: 04/07/2017 09:47 PM] (1715) |
| Apr 7, 2017 | 140 | CONFIDENTIAL JOINT APPENDIX FILED for Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC [138], [137]. Number of Pages: 1709. Service: 04/07/2017 by email. The paper copies of the confidential appendix should be received by the court on or before 04/17/2017. [422790] [JCA] [Entered: 04/10/2017 02:15 PM] (0) |
| Apr 7, 2017 | 141 | APPENDIX FILED for Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC [139]. Number of Pages: 1715. Service: 04/07/2017 by email. [422797] [JCA] [Entered: 04/10/2017 02:20 PM] (1715) |
| Apr 4, 2017 | 135 | 6 paper copies of the Reply Brief [130] received from Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. [421373] [KW] [Entered: 04/04/2017 02:58 PM] (0) |
| Apr 3, 2017 | 131 | Notice from Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC regarding conflicts with oral argument (April 3-21; May 4-10, 17-18, 31; June 1-2, 5, 9, 12-23; July 10-14). Service: 04/03/2017 by email. [420910] [Paul Clement] [Entered: 04/03/2017 12:26 PM] (1) |
| Apr 3, 2017 | 134 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: Notice regarding the ECF account of Michael A. Morin for AbbVie Inc. The e-mail address, (richard.hildreth@lw.com), associated with your CM/ECF account has generated a delivery failure notice. Counsel should promptly report a change in contact information with the Pacer Service Center (see Fed. Cir. R. 47.3(c)(1). [421031] [PMM] [Entered: 04/03/2017 03:27 PM] (0) |
| Mar 31, 2017 | 127 | Clerk's Note to the File: Amicus AbbVie Inc. is directed to file a Certificate of Interest. While one was included in the brief it needs to be included on the docket sheet as an independent filing. (Ref: [126]) [420565] [JCA] [Entered: 03/31/2017 09:58 AM] (0) |
| Mar 31, 2017 | 128 | Certificate of Interest for the Amicus Curiae AbbVie Inc.. Service: 03/31/2017 by email. [420632] [Melissa Sherry] [Entered: 03/31/2017 12:20 PM] (3) |
| Mar 31, 2017 | 129 | TENDERED from Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Title: REPLY BRIEF. Service: 03/31/2017 by email. [420780] [Paul Clement] [Entered: 03/31/2017 07:04 PM] (43) |
| Mar 31, 2017 | 130 | REPLY BRIEF FILED for Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC [129]. Number of Pages: 32. Service: 03/31/2017 by email. The paper copies of the brief should be received by the court on or before 04/10/2017. Appendix is due 04/07/2017. [420823] [JCA] [Entered: 04/03/2017 09:19 AM] (43) |
| Mar 31, 2017 | 132 | 6 paper copies of the Amicus Brief [126] received from Amicus Curiae AbbVie Inc. [420957] [KW] [Entered: 04/03/2017 01:30 PM] (0) |
| Mar 31, 2017 | 133 | 6 paper copies of the Response Brief [120] received from Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc. [420984] [KW] [Entered: 04/03/2017 02:13 PM] (0) |
| Mar 30, 2017 | 122 | Entry of appearance for Melissa Arbus Sherry as principal counsel for AbbVie Inc.. Service: 03/30/2017 by email. [420474] [Melissa Sherry] [Entered: 03/30/2017 04:39 PM] (3) |
| Mar 30, 2017 | 123 | Entry of appearance for Michael A. Morin as of counsel for AbbVie Inc.. Service: 03/30/2017 by email. [420479] [Michael Morin] [Entered: 03/30/2017 04:42 PM] (3) |
| Mar 30, 2017 | 124 | Entry of appearance for Emily K. Sauter as of counsel for AbbVie Inc.. Service: 03/30/2017 by email. [420485] [Emily Sauter] [Entered: 03/30/2017 04:46 PM] (3) |
| Mar 30, 2017 | 125 | TENDERED from AbbVie Inc. Title: AMICUS CURIAE BRIEF. Service: 03/30/2017 by email. [420490] [Melissa Sherry] [Entered: 03/30/2017 04:52 PM] (35) |
| Mar 30, 2017 | 126 | AMICUS BRIEF FILED for AbbVie Inc. [125]. Number of Pages: 26. Service: 03/30/2017 by email. The paper copies of the brief should be received by the court on or before 04/07/2017. [420564] [JCA] [Entered: 03/31/2017 09:57 AM] (35) |
| Mar 27, 2017 | 121 | 6 paper copies of the Amicus Brief [117] received from Amici Curiae Doctor Luis Aparicio, M.D., Doctor W. Ross Davis, M.D., et al. [419569] [KW] [Entered: 03/28/2017 02:08 PM] (0) |
| Mar 24, 2017 | 118 | Certificate of Interest for the Amici Curiae Doctor Luis Aparicio, M.D., Doctor W. Ross Davis, M.D., Rosa DeBernardo, Doctor Avichai Eres, M.D., Doctor Norman Lepor, M.D., Doctor Mary McGowan, M.D., Doctor Narendra Singh, M.D., Doctor Paul Thompson, M.D. and Alina Wilson. Service: 03/24/2017 by email. [418719] [William Marsillo] [Entered: 03/24/2017 12:33 PM] (3) |
| Mar 24, 2017 | 119 | TENDERED from Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Title: RESPONSE BRIEF. Service: 03/24/2017 by email. [418914] [Daryl Joseffer] [Entered: 03/24/2017 07:42 PM] (98) |
| Mar 24, 2017 | 120 | BRIEF FILED for Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc. [119]. Number of Pages: 82. Service: 03/24/2017 by email. The paper copies of the brief should be received by the court on or before 04/03/2017. Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC reply brief is due 03/31/2017 pursuant to court order. [418956] [JCA] [Entered: 03/27/2017 09:15 AM] (98) |
| Mar 22, 2017 | 115 | ORDER filed. The motion [86] is granted. The amici brief is accepted for filing. Service: 03/22/2017 by clerk. [418015] [LMS] [Entered: 03/22/2017 03:25 PM] (3) |
| Mar 22, 2017 | 116 | TENDERED from Amici Curiae Doctor Luis Aparicio, M.D., Doctor W. Ross Davis, M.D., Rosa DeBernardo, Doctor Avichai Eres, M.D., Doctor Norman Lepor, M.D., Doctor Mary McGowan, M.D., Doctor Narendra Singh, M.D., Doctor Paul Thompson, M.D. and Alina Wilson. Title: AMICUS CURIAE BRIEF. Brief tendered by the clerk's office for the purpose of filing. [418107] [JCA] [Entered: 03/22/2017 05:00 PM] (32) |
| Mar 22, 2017 | 117 | AMICUS BRIEF FILED for Doctor Luis Aparicio, M.D., Doctor W. Ross Davis, M.D., Rosa DeBernardo, Doctor Avichai Eres, M.D., Doctor Norman Lepor, M.D., Doctor Mary McGowan, M.D., Doctor Narendra Singh, M.D., Doctor Paul Thompson, M.D. and Alina Wilson [116]. Number of Pages: 25. Service: 02/24/2017 by email. The paper copies of the brief should be received by the court on or before 03/29/2017. [418108] [JCA] [Entered: 03/22/2017 05:02 PM] (32) |
| Mar 21, 2017 | 114 | Notice from Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc. regarding conflicts with oral argument (April 26, May 19, May 30, June 26-30, and July 1-8). Service: 03/21/2017 by email. [417338] [Daryl Joseffer] [Entered: 03/21/2017 11:11 AM] (2) |
| Mar 9, 2017 | 113 | REPLY of Amici Curiae, Physicians and Patients to response filed by Appellees in 17-1480 , Doc. No [108]. Service: 03/09/2017 by email. [414166] [William Marsillo] [Entered: 03/09/2017 06:59 PM] (19) |
| Mar 8, 2017 | 109 | 6 paper copies of the Corrected Opening Brief [106] received from Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. [413426] [KW] [Entered: 03/08/2017 01:36 PM] (0) |
| Mar 8, 2017 | 110 | Letter from Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC Oral Argument Availability. Service: 03/08/2017 by email. [413504] [Paul Clement] [Entered: 03/08/2017 03:18 PM] (0) |
| Mar 8, 2017 | 111 | NOTICE OF DEFICIENCY: The party letter Document No. [110] filed by Appellants Sanofi-Aventis U.S., LLC, Sanofi, Aventisub LLC and Regeneron Pharmaceuticals Inc. in 17-1480 is submitted using the incorrect event and therefore cannot be accepted for filing at this time (Document must be refiled under the "Notice Regarding Conflicts with Argument Dates" event). You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [413508] [JAB] [Entered: 03/08/2017 03:21 PM] (0) |
| Mar 8, 2017 | 112 | Notice from Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC regarding conflicts with oral argument (April 3-21; May 4-10, 17-18, 31; June 1-2, 12-23; July 11). Service: 03/08/2017 by email. [413524] [Paul Clement] [Entered: 03/08/2017 03:29 PM] (1) |
| Mar 6, 2017 | 107 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: Notice regarding the ECF account of Mr. David A. Kelly for Ipsen Pharma S.A.S. The e-mail address, (jkersten@hunton.com), associated with your CM/ECF account has generated a delivery failure notice. Counsel should promptly report a change in contact information with the Pacer Service Center (see Fed. Cir. R. 47.3(c)(1). [412765] [PMM] [Entered: 03/06/2017 02:21 PM] (0) |
| Mar 6, 2017 | 108 | RESPONSE of Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc. to the motion for leave to file an amicus curiae brief [86]. Service: 03/06/2017 by email. [412866] [Daryl Joseffer] [Entered: 03/06/2017 07:42 PM] (120) |
| Mar 3, 2017 | 104 | Notice of Correction to the Brief Doc No. [62] for Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Service: 03/03/2017 by email. [412546] [Paul Clement] [Entered: 03/03/2017 06:20 PM] (9) |
| Mar 3, 2017 | 105 | TENDERED from Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Title: CORRECTED OPENING BRIEF. Service: 03/03/2017 by email. [412547] [Paul Clement] [Entered: 03/03/2017 06:22 PM] (118) |
| Mar 3, 2017 | 106 | CORRECTED BRIEF FILED for Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC [105]. Number of Pages: 65. Service: 03/03/2017 by email. The paper copies of the brief should be received by the court on or before 03/13/2017. [412645] [JCA] [Entered: 03/06/2017 10:32 AM] (118) |
| Mar 1, 2017 | 103 | 6 paper copies of the Amicus Brief [79] received from Amici Curiae AARP and AARP Foundation. [411645] [KW] [Entered: 03/01/2017 12:57 PM] (0) |
| Feb 28, 2017 | 102 | 6 paper copies of the Amicus Brief [96] received from Amici Curiae Ipsen Pharma S.A.S. and Pfizer Inc. [411296] [KW] [Entered: 02/28/2017 02:34 PM] (0) |
| Feb 27, 2017 | 93 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re: Brief Docket No. [92], ERROR: The brief list Ipsen Pharma S.A.S. as a party however no one has filed an Entry of Appearance on their behalf. The brief lists David A. Kelly as their counsel, however the EOA he filed on Friday was submitted on behalf of Pfizer Inc. CORRECTION: David A. Kelly needs to file an Entry of Appearance indicating he is principal counsel for Ipsen Pharma S.A.S. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [410679] [JCA] [Entered: 02/27/2017 09:35 AM] (0) |
| Feb 27, 2017 | 94 | NOTICE OF DEFICIENCY: The attorney entry of appearance Document No. [89] cannot be accepted for filing at this time. The document was submitted on behalf of Pfizer Inc., however the form itself lists Ipsen Pharma S.A.S. as the party you are appearing for. You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [410682] [JCA] [Entered: 02/27/2017 09:39 AM] (0) |
| Feb 27, 2017 | 95 | Corrected Entry of appearance for David A. Kelly as principal counsel for Ipsen Pharma S.A.S. Service: 02/27/2017 by email. [410707] [David Kelly] [Entered: 02/27/2017 10:05 AM] (1) |
| Feb 27, 2017 | 97 | Clerk's Note to the File: Ipsen Pharma S.A.S. Pfizer Inc. and are directed to file Certificates of Interest. While they were included in the brief they need to be filed on the docket sheet as an independent filing. [410762] [JCA] [Entered: 02/27/2017 11:52 AM] (0) |
| Feb 27, 2017 | 98 | Certificate of Interest for the Amicus Curiae Ipsen Pharma S.A.S.. Service: 02/27/2017 by email. [410817] [David Kelly] [Entered: 02/27/2017 01:30 PM] (1) |
| Feb 27, 2017 | 99 | Certificate of Interest for the Amicus Curiae Pfizer Inc.. Service: 02/27/2017 by email. [410826] [Dimitrios Drivas] [Entered: 02/27/2017 01:53 PM] (2) |
| Feb 27, 2017 | 100 | 6 paper copies of the Amicus Brief [75] received from Amicus Curiae Eli Lilly and Company. [410847] [KW] [Entered: 02/27/2017 02:19 PM] (0) |
| Feb 27, 2017 | 101 | ORDER filed. Any opposition to the motion [86] shall be filed no later than seven days from the date of issuance of this order. Any reply is due no later than three days from the filing of the response. Service: 02/27/2017 by clerk. [410957] [LMS] [Entered: 02/27/2017 03:57 PM] (2) |
| Feb 24, 2017 | 83 | 6 paper copies of the Opening Brief [64] received from Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. [410468] [KW] [Entered: 02/24/2017 01:40 PM] (0) |
| Feb 24, 2017 | 84 | Entry of appearance for William D. Marsillo as principal counsel for Amici Curiae, Physicians and Patients. Service: 02/24/2017 by email. [410574] [William Marsillo] [Entered: 02/24/2017 04:26 PM] (2) |
| Feb 24, 2017 | 85 | Entry of appearance for Michael D. Jay as of counsel for Amici Curiae, Physicians and Patients. Service: 02/24/2017 by email. [410578] [William Marsillo] [Entered: 02/24/2017 04:29 PM] (2) |
| Feb 24, 2017 | 86 | MOTION of Amici Curiae, Physicians and Patients for leave to file an amicus curiae brief. Any response is due within 10 days of service [Consent: partial consent]. Service: 02/24/2017 by email. [410605] [William Marsillo] [Entered: 02/24/2017 06:29 PM] (43) |
| Feb 24, 2017 | 87 | Entry of appearance for Dimitrios T. Drivas as principal counsel for Pfizer Inc.. Service: 02/24/2017 by email. [410618] [Dimitrios Drivas] [Entered: 02/24/2017 08:30 PM] (2) |
| Feb 24, 2017 | 88 | Entry of appearance for Amit H. Thakore as of counsel for Pfizer Inc.. Service: 02/24/2017 by email. [410619] [Dimitrios Drivas] [Entered: 02/24/2017 08:35 PM] (2) |
| Feb 24, 2017 | 89 | Entry of appearance for David A. Kelly as of counsel for Pfizer Inc.. Service: 02/24/2017 by email. [410620] [Dimitrios Drivas] [Entered: 02/24/2017 08:36 PM] (0) |
| Feb 24, 2017 | 90 | Entry of appearance for Eric M. Majchrzak as of counsel for Pfizer Inc.. Service: 02/24/2017 by email. [410621] [Dimitrios Drivas] [Entered: 02/24/2017 08:38 PM] (2) |
| Feb 24, 2017 | 91 | Entry of appearance for Jeffrey N. Myers as of counsel for Pfizer Inc.. Service: 02/24/2017 by email. [410622] [Dimitrios Drivas] [Entered: 02/24/2017 08:40 PM] (2) |
| Feb 24, 2017 | 92 | TENDERED from Pfizer Inc., Ipsen Pharma S.A.S. Title: AMICUS CURIAE BRIEF. Service: 02/24/2017 by email. [410623]--[Edited 02/27/2017 by clerk to add Ipsen Pharma S.A.S. as a party] [Dimitrios Drivas] [Entered: 02/24/2017 08:43 PM] (34) |
| Feb 24, 2017 | 96 | AMICUS BRIEF FILED for Ipsen Pharma S.A.S. and Pfizer Inc. [92]. Number of Pages: 26. Service: 02/24/2017 by email. The paper copies of the brief should be received by the court on or before 03/06/2017. [410761] [JCA] [Entered: 02/27/2017 11:50 AM] (34) |
| Feb 23, 2017 | 68 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:attorney entry of appearance Docket No. [66], ERROR: The contact information we have for you (Richard Praseuth) does not include the name of your firm. CORRECTION: Update your contact information with the PACER service information to include the name of your firm, not just the address. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [409850] [JCA] [Entered: 02/23/2017 08:40 AM] (0) |
| Feb 23, 2017 | 69 | Entry of appearance for Duane C. Marks as principal counsel for Amicus Curiae, Eli Lilly and Company. Service: 02/23/2017 by email. [409968] [Duane Marks] [Entered: 02/23/2017 11:17 AM] (2) |
| Feb 23, 2017 | 70 | Entry of appearance for Gilbert Voy as of counsel for Amicus Curiae, Eli Lilly and Company. Service: 02/23/2017 by email. [409971] [Duane Marks] [Entered: 02/23/2017 11:19 AM] (2) |
| Feb 23, 2017 | 71 | Entry of appearance for Alexander Wilson as of counsel for Amicus Curiae, Eli Lilly and Company. Service: 02/23/2017 by email. [409973] [Duane Marks] [Entered: 02/23/2017 11:21 AM] (2) |
| Feb 23, 2017 | 72 | Entry of appearance for Gregory A. Cox as of counsel for Amicus Curiae, Eli Lilly and Company. Service: 02/23/2017 by email. [409974] [Duane Marks] [Entered: 02/23/2017 11:22 AM] (2) |
| Feb 23, 2017 | 73 | TENDERED from Amicus Curiae, Eli Lilly and Company Title: AMICUS CURIAE BRIEF. Service: 02/23/2017 by email. [410009] [Duane Marks] [Entered: 02/23/2017 12:10 PM] (36) |
| Feb 23, 2017 | 74 | Entry of appearance for Katherine Nicole Clouse as of counsel for Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 02/23/2017 by email. [410037] [Katherine Clouse] [Entered: 02/23/2017 12:42 PM] (2) |
| Feb 23, 2017 | 75 | AMICUS BRIEF FILED for Eli Lilly and Company [73]. Number of Pages: 29. Service: 02/23/2017 by email. The paper copies of the brief should be received by the court on or before 03/02/2017. [410074] [JCA] [Entered: 02/23/2017 01:38 PM] (36) |
| Feb 23, 2017 | 76 | Clerk's Note to the File: Amicus Eli Lilly and Company is directed to file a Certificate of Interest. While one was included in the brief it needs to be filed on the docket sheet as an independent filing. (Ref: [75]) [410076] [JCA] [Entered: 02/23/2017 01:40 PM] (0) |
| Feb 23, 2017 | 77 | Entry of appearance for Barbara Anne Jones as principal counsel for Amicus Curiae AARP and AARP Foundation. Service: 02/23/2017 by email. [410103] [Barbara Jones] [Entered: 02/23/2017 02:26 PM] (2) |
| Feb 23, 2017 | 78 | TENDERED from AARP and AARP Foundation Title: AMICUS CURIAE BRIEF. Service: 02/23/2017 by email. [410115] [Barbara Jones] [Entered: 02/23/2017 02:53 PM] (19) |
| Feb 23, 2017 | 79 | AMICUS BRIEF FILED for AARP and AARP Foundation [78]. Number of Pages: 10. Service: 02/23/2017 by email. The paper copies of the brief should be received by the court on or before 03/02/2017. [410183] [JCA] [Entered: 02/23/2017 04:02 PM] (17) |
| Feb 23, 2017 | 80 | Clerk's Note to the File: Amicus AARP and AARP Foundation are directed to file a Certificate of Interest. While one was included in the brief it needs to be filed on the docket sheet as an independent filing. (Ref: [79]) [410185] [JCA] [Entered: 02/23/2017 04:04 PM] (0) |
| Feb 23, 2017 | 81 | Certificate of Interest for the Amici Curiae AARP and AARP Foundation. Service: 02/23/2017 by email. [410198] [Barbara Jones] [Entered: 02/23/2017 04:28 PM] (2) |
| Feb 23, 2017 | 82 | Certificate of Interest for the Amicus Curiae Eli Lilly and Company. Service: 02/23/2017 by email. [410232] [Duane Marks] [Entered: 02/23/2017 04:59 PM] (2) |
| Feb 22, 2017 | 65 | Entry of appearance for Kiley Ann White as of counsel for Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Service: 02/22/2017 by email. [409752] [Kiley White] [Entered: 02/22/2017 03:47 PM] (2) |
| Feb 22, 2017 | 66 | Entry of appearance for Richard Praseuth as of counsel for Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Service: 02/22/2017 by email. [409797] [Richard Praseuth] [Entered: 02/22/2017 04:48 PM] (2) |
| Feb 22, 2017 | 67 | Entry of appearance for Siew Yen Chong as of counsel for Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Service: 02/22/2017 by email. [409798] [Siew Chong] [Entered: 02/22/2017 04:55 PM] (2) |
| Feb 21, 2017 | 63 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a)and Fed. Cir. R. 47.3 to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [408906] [JCA] [Entered: 02/21/2017 08:47 AM] (0) |
| Feb 17, 2017 | 62 | TENDERED from Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Title: OPENING BRIEF. Service: 02/17/2017 by email. [408862]. This brief has been replaced. See Doc No.[106] [Paul Clement] [Entered: 02/17/2017 07:44 PM] (0) |
| Feb 17, 2017 | 64 | BRIEF FILED for Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC [62]. Number of Pages: 65. Service: 02/17/2017 by email. The paper copies of the brief should be received by the court on or before 02/28/2017. Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc. brief is due 03/24/2017 pursuant to court order issued on 01/18/2017. [408916]. This brief has been replaced. See Doc No.[106] [JCA] [Entered: 02/21/2017 09:00 AM] (0) |
| Feb 15, 2017 | 60 | Entry of appearance for Steven D. Tang as of counsel for Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 02/15/2017 by email. [407711] [Steven Tang] [Entered: 02/15/2017 12:43 PM] (2) |
| Feb 15, 2017 | 61 | Entry of appearance for Merritt E. McAlister as of counsel for Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 02/15/2017 by email. [407713] [Merritt McAlister] [Entered: 02/15/2017 12:48 PM] (2) |
| Feb 8, 2017 | 59 | ORDER filed. The motion to stay the injunction pending appeal [14] is granted. All other pending motions [33] [36] are denied as moot. Service: 02/08/2017 by clerk. [405742] [LMS] [Entered: 02/08/2017 04:04 PM] (2) |
| Feb 1, 2017 | 58 | REPLY of Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC to response filed by Appellees in 17-1480 , Doc. No [56]. Service: 02/01/2017 by email. [404002] [Paul Clement] [Entered: 02/01/2017 05:59 PM] (150) |
| Jan 31, 2017 | 57 | Entry of appearance for Wendy A. Whiteford as of counsel for Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 01/31/2017 by email. [403484] [Wendy Whiteford] [Entered: 01/31/2017 03:04 PM] (2) |
| Jan 27, 2017 | 54 | REPLY of Dr. W. Ross Davis, MD; Dr. Mary P. McGowan, MD; Dr. Avichai Eres, MD; Dr. Michael G. Clark, PhD. to response filed by Appellees in 17-1480 , Doc. No [49]. Service: 01/27/2017 by email. [402734] [George Lyons] [Entered: 01/27/2017 03:31 PM] (12) |
| Jan 27, 2017 | 55 | REPLY of Dr. Luis F. Aparicio, MD to response filed by Appellees in 17-1480 , Doc. No [49]. Service: 01/27/2017 by email. [402738] [Eric Marandett] [Entered: 01/27/2017 03:36 PM] (8) |
| Jan 27, 2017 | 56 | RESPONSE of Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc. to the motion for emergency stay pending appeal [14] filed by Appellants Sanofi-Aventis U.S., LLC, Sanofi, Aventisub LLC and Regeneron Pharmaceuticals Inc. in 17-1480 , motion to expedite briefing schedule [14] filed by Appellants Sanofi-Aventis U.S., LLC, Sanofi, Aventisub LLC and Regeneron Pharmaceuticals Inc. in 17-1480. Service: 01/27/2017 by email. [402840] [Daryl Joseffer] [Entered: 01/27/2017 08:29 PM] (1208) |
| Jan 26, 2017 | 50 | Docketing Statement for the Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 01/26/2017 by email. [402392] [Daryl Joseffer] [Entered: 01/26/2017 03:27 PM] (3) |
| Jan 26, 2017 | 51 | Docketing Statement for the Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Service: 01/26/2017 by email. [402396] [Paul Clement] [Entered: 01/26/2017 03:35 PM] (3) |
| Jan 26, 2017 | 52 | Amended Certificate of Interest for the Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Service: 01/26/2017 by email. [402398] [Paul Clement] [Entered: 01/26/2017 03:37 PM] (2) |
| Jan 26, 2017 | 53 | Entry of appearance for Nathan S. Mammen as of counsel for Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Service: 01/26/2017 by email. [402416] [Nathan Mammen] [Entered: 01/26/2017 04:00 PM] (2) |
| Jan 25, 2017 | 49 | RESPONSE of Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc. to the motion for leave to file an amicus curiae brief [33] , motion for leave to file an amicus curiae brief [36]. Service: 01/25/2017 by email. [401805] [Daryl Joseffer] [Entered: 01/25/2017 12:09 PM] (25) |
| Jan 24, 2017 | 38 | Notice of Rejection to Dr. W. Ross Davis, MD; Dr. Mary P. McGowan, MD; Dr. Avichai Eres, MD; Dr. Michael G. Clark, PhD , the following document(s): motion to file amicus response to motion [34] is REJECTED for filing. Reason(s): Incorrect event used. Service: 01/24/2017 by clerk. [401136] [JCA] [Entered: 01/24/2017 09:09 AM] (1) |
| Jan 24, 2017 | 39 | Notice of Rejection to Dr. Luis F. Aparicio, MD , the following document(s): motion to file amicus response to motion [37] is REJECTED for filing. Reason(s): Incorrect event used. Service: 01/24/2017 by clerk. [401144] [JCA] [Entered: 01/24/2017 09:19 AM] (1) |
| Jan 24, 2017 | 40 | RESPONSE from Dr. W. Ross David, MD; Dr. Mary P. McGowan, MD; Dr. Avichai Eres, MD; Dr. Michael G. Clark, PhD to the motion for emergency stay pending appeal [14] filed by Appellants Sanofi-Aventis U.S., LLC, Sanofi, Aventisub LLC and Regeneron Pharmaceuticals Inc. in 17-1480 , motion to expedite briefing schedule [14] filed by Appellants Sanofi-Aventis U.S., LLC, Sanofi, Aventisub LLC and Regeneron Pharmaceuticals Inc. in 17-1480. Service: 01/24/2017 by email. [401260] [George Lyons] [Entered: 01/24/2017 10:58 AM] (18) |
| Jan 24, 2017 | 41 | RESPONSE from Dr. Luis F. Aparicio, MD to the motion for emergency stay pending appeal [14] filed by Appellants Sanofi-Aventis U.S., LLC, Sanofi, Aventisub LLC and Regeneron Pharmaceuticals Inc. in 17-1480 , motion to expedite briefing schedule [14] filed by Appellants Sanofi-Aventis U.S., LLC, Sanofi, Aventisub LLC and Regeneron Pharmaceuticals Inc. in 17-1480. Service: 01/24/2017 by email. [401265] [Eric Marandett] [Entered: 01/24/2017 11:03 AM] (13) |
| Jan 24, 2017 | 42 | ORDER filed. Any opposition to the motions [33] [36] shall be filed no later than January 30, 2017. Any reply is due no later than two days from the filing of the response. Service: 01/24/2017 by clerk. [401395] [LMS] [Entered: 01/24/2017 01:35 PM] (0) |
| Jan 24, 2017 | 43 | Entry of appearance for Erica S. Olson as of counsel for Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 01/24/2017 by email. [401408] [Erica Olson] [Entered: 01/24/2017 01:45 PM] (2) |
| Jan 24, 2017 | 44 | Entry of appearance for Dennis J. Smith as of counsel for Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 01/24/2017 by email. [401413] [Dennis Smith] [Entered: 01/24/2017 01:50 PM] (2) |
| Jan 24, 2017 | 45 | Entry of appearance for Stuart L. Watt as of counsel for Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 01/24/2017 by email. [401416] [Stuart Watt] [Entered: 01/24/2017 01:53 PM] (2) |
| Jan 24, 2017 | 46 | Entry of appearance for Emily Curtis Johnson as of counsel for Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 01/24/2017 by email. [401495] [Emily Johnson] [Entered: 01/24/2017 03:36 PM] (2) |
| Jan 24, 2017 | 47 | CORRECTED ORDER: correcting clerk order for expedited response or reply [42]; reason(s): to distinguish that the motions for leave to file a brief amici curiae and a brief amicus curiae are in support of the appellants' motion for a stay pending appeal. Service: 01/24/2017 by clerk. [401547] [LMS] [Entered: 01/24/2017 04:26 PM] (2) |
| Jan 24, 2017 | 48 | Amended Certificate of Interest for the Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 01/24/2017 by email. [401611] [Daryl Joseffer] [Entered: 01/24/2017 10:14 PM] (2) |
| Jan 23, 2017 | 28 | Entry of appearance for Melanie K. Sharp as of counsel for Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 01/23/2017 by email. [400699] [Melanie Sharp] [Entered: 01/23/2017 10:50 AM] (2) |
| Jan 23, 2017 | 29 | Transcript Purchase Order Form for the Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC indicating that a request is made to the reporter for a transcript. Service: 01/23/2017 by email. [400946] [George Hicks] [Entered: 01/23/2017 04:11 PM] (3) |
| Jan 23, 2017 | 30 | Entry of appearance for Paul H. Berghoff as principal counsel for Dr. W. Ross Davis, MD; Dr. Mary P. McGowan, MD; Dr. Avichai Eres, MD; Dr. Michael G. Clark, MD. Service: 01/23/2017 by email. [400956] [George Lyons] [Entered: 01/23/2017 04:20 PM] (6) |
| Jan 23, 2017 | 31 | Entry of appearance for James L. Lovsin as of counsel for Dr. W. Ross Davis, MD; Dr. Mary P. McGowan, MD; Dr. Avichai Eres, MD; Dr. Michael G. Clark, PhD. Service: 01/23/2017 by email. [400966] [George Lyons] [Entered: 01/23/2017 04:28 PM] (6) |
| Jan 23, 2017 | 32 | Entry of appearance for George T. Lyons, III as of counsel for Dr. W. Ross Davis, MD; Dr. Mary P. McGowan, MD; Dr. Avichai Eres, MD; Dr. Michael G. Clark, PhD. Service: 01/23/2017 by email. [400969] [George Lyons] [Entered: 01/23/2017 04:30 PM] (6) |
| Jan 23, 2017 | 33 | MOTION of Dr. W. Ross Davis, MD; Dr. Mary P. McGowan, MD; Dr. Avichai Eres, MD; Dr. Michael G. Clark, PhD for leave to file an amicus curiae brief. Any response is due within 10 days of service [Consent: partial consent]. Service: 01/23/2017 by email. [400973] [George Lyons] [Entered: 01/23/2017 04:32 PM] (12) |
| Jan 23, 2017 | 34 | MOTION of Dr. W. Ross Davis, MD; Dr. Mary P. McGowan, MD; Dr. Avichai Eres, MD; Dr. Michael G. Clark, PhD to file an amicus response to the motion for emergency stay pending appeal [14] filed by Appellants Sanofi-Aventis U.S., LLC, Sanofi, Aventisub LLC and Regeneron Pharmaceuticals Inc. in 17-1480 , motion to expedite briefing schedule [14] filed by Appellants Sanofi-Aventis U.S., LLC, Sanofi, Aventisub LLC and Regeneron Pharmaceuticals Inc. in 17-1480 [Consent: partial consent]. Service: 01/23/2017 by email. [400974] [George Lyons] [Entered: 01/23/2017 04:34 PM] (18) |
| Jan 23, 2017 | 35 | Entry of appearance for Eric J. Marandett as principal counsel for Dr. Luis F. Aparicio, MD. Service: 01/23/2017 by email. [400996] [Eric Marandett] [Entered: 01/23/2017 05:23 PM] (5) |
| Jan 23, 2017 | 36 | MOTION of Dr. Luis F. Aparicio, MD for leave to file an amicus curiae brief. Any response is due within 10 days of service [Consent: partial consent]. Service: 01/23/2017 by email. [400998] [Eric Marandett] [Entered: 01/23/2017 05:24 PM] (10) |
| Jan 23, 2017 | 37 | MOTION of Dr. Luis F. Aparicio, MD to file an amicus response to the motion for emergency stay pending appeal [14] filed by Appellants Sanofi-Aventis U.S., LLC, Sanofi, Aventisub LLC and Regeneron Pharmaceuticals Inc. in 17-1480 , motion to expedite briefing schedule [14] filed by Appellants Sanofi-Aventis U.S., LLC, Sanofi, Aventisub LLC and Regeneron Pharmaceuticals Inc. in 17-1480 [Consent: partial consent]. Service: 01/23/2017 by email. [400999] [Eric Marandett] [Entered: 01/23/2017 05:27 PM] (13) |
| Jan 19, 2017 | 25 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: Re: Attorney Entry of Appearance for Eric W. Hagen Docket No. [24], includes contact information on the form that does not match the information associated with his CM/ECF account. CORRECTION: Counsel should promptly report a change in contact information with the Pacer Service Center. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [400313] [CMP] [Entered: 01/19/2017 10:36 AM] (0) |
| Jan 19, 2017 | 26 | Entry of appearance for Christopher B. Mead as of counsel for Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 01/19/2017 by email. [400333] [Christopher Mead] [Entered: 01/19/2017 10:59 AM] (2) |
| Jan 19, 2017 | 27 | Entry of appearance for Sarah C. Columbia as of counsel for Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 01/19/2017 by email, clerk. [400526] [Sarah Columbia] [Entered: 01/19/2017 04:46 PM] (2) |
| Jan 18, 2017 | 20 | Letter from Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC Responding to Appellees' Letter. Service: 01/18/2017 by email. [399875] [Paul Clement] [Entered: 01/18/2017 11:20 AM] (4) |
| Jan 18, 2017 | 21 | Entry of appearance for Christopher R. Healy as of counsel for Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 01/18/2017 by email. [399995] [Christopher Healy] [Entered: 01/18/2017 01:55 PM] (2) |
| Jan 18, 2017 | 22 | ORDER filed. The appellees are directed to respond to the motion [14] within ten days from the date of filing of this order. Any reply must be received within five days from the date of filing of the response. The appellants’ opening brief is due within 30 days from the date of filing of this order. The appellees’ response brief is due no later than 35 days thereafter. The appellants’ reply brief is due no later than seven days thereafter. Service: 01/18/2017 by clerk. [399996] [LMS] [Entered: 01/18/2017 01:57 PM] (2) |
| Jan 18, 2017 | 23 | Entry of appearance for William G Gaede, III as of counsel for Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 01/18/2017 by email, clerk. [400031] [William Gaede] [Entered: 01/18/2017 02:20 PM] (2) |
| Jan 18, 2017 | 24 | Entry of appearance for Eric W. Hagen as of counsel for Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 01/17/2017 by email, clerk. [400228] [Eric Hagen] [Entered: 01/18/2017 08:32 PM] (2) |
| Jan 17, 2017 | 16 | Letter from Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc. Briefing Schedule Proposal. Service: 01/17/2017 by email. [399265] [Daryl Joseffer] [Entered: 01/17/2017 08:31 AM] (10) |
| Jan 17, 2017 | 17 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re: motion for emergency stay pending appeal Docket No. [14], motion to expedite briefing schedule Docket No. [14], ERROR: The motion lists John J. Molenda and Vishal C. Gupta as counsel for the defendants-appellants. Neither of these individuals has filed an entry of appearance. CORRECTION: If John J. Molenda and Vishal C. Gupta intend to appear on behalf of the appellants they need to file an entry of appearance. Until they do so, their names should not appear on any documents filed in this appeal. The motion is not being rejected as it was signed by Mr. Clement who has properly appeared in this appeal. There is no need to refile the motion. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [399373] [JCA] [Entered: 01/17/2017 10:48 AM] (0) |
| Jan 17, 2017 | 18 | Entry of appearance for John Josef Molenda as of counsel for Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Service: 01/17/2017 by email. [399491] [John Molenda] [Entered: 01/17/2017 01:21 PM] (2) |
| Jan 17, 2017 | 19 | Entry of appearance for Vishal C. Gupta as of counsel for Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Service: 01/17/2017 by email. [399495] [Vishal Gupta] [Entered: 01/17/2017 01:24 PM] (2) |
| Jan 13, 2017 | 2 | Entry of appearance for Paul D. Clement as principal counsel for Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Service: 01/13/2017 by email. [398973] [Paul Clement] [Entered: 01/13/2017 09:57 AM] (0) |
| Jan 13, 2017 | 3 | Entry of appearance for George W. Hicks, Jr. as of counsel for Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Service: 01/13/2017 by email. [398978] [George Hicks] [Entered: 01/13/2017 09:59 AM] (0) |
| Jan 13, 2017 | 4 | Entry of appearance for Christopher G. Michel as of counsel for Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Service: 01/13/2017 by email. [398982] [Christopher Michel] [Entered: 01/13/2017 10:02 AM] (0) |
| Jan 13, 2017 | 5 | Certificate of Interest for the Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Service: 01/13/2017 by email. [398984] [Paul Clement] [Entered: 01/13/2017 10:04 AM] (0) |
| Jan 13, 2017 | 6 | NOTICE OF DEFICIENCY: The certificate of interest Document No. [5] filed by Appellants Sanofi-Aventis U.S., LLC, Sanofi, Aventisub LLC and Regeneron Pharmaceuticals Inc. in 17-1480 , attorney entry of appearance Document No. [4] filed by Appellants Sanofi-Aventis U.S., LLC, Sanofi, Aventisub LLC and Regeneron Pharmaceuticals Inc. in 17-1480 , attorney entry of appearance Document No. [3] filed by Appellants Sanofi-Aventis U.S., LLC, Sanofi, Aventisub LLC and Regeneron Pharmaceuticals Inc. in 17-1480 , attorney entry of appearance Document No. [2] filed by Appellants Sanofi-Aventis U.S., LLC, Sanofi, Aventisub LLC and Regeneron Pharmaceuticals Inc. in 17-1480 is without a proper/complete proof of service and therefore cannot be accepted for filing at this time. You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [398987] [JCA] [Entered: 01/13/2017 10:19 AM] (0) |
| Jan 13, 2017 | 7 | Corrected Entry of appearance for Paul D. Clement as principal counsel for Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Service: 01/13/2017 by email. [399003] [Paul Clement] [Entered: 01/13/2017 10:52 AM] (2) |
| Jan 13, 2017 | 8 | Corrected Entry of appearance for George W. Hicks, Jr. as of counsel for Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Service: 01/13/2017 by email. [399005] [George Hicks] [Entered: 01/13/2017 10:58 AM] (2) |
| Jan 13, 2017 | 9 | Corrected Entry of appearance for Christopher G. Michel as of counsel for Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Service: 01/13/2017 by email. [399008] [Christopher Michel] [Entered: 01/13/2017 11:01 AM] (2) |
| Jan 13, 2017 | 10 | Corrected Certificate of Interest for the Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Service: 01/13/2017 by email. [399010] [Paul Clement] [Entered: 01/13/2017 11:03 AM] (2) |
| Jan 13, 2017 | 11 | Entry of appearance for Joshua N. Mittchell as of counsel for Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 01/13/2017 by email. [399192] [Joshua Mitchell] [Entered: 01/13/2017 05:06 PM] (2) |
| Jan 13, 2017 | 12 | Entry of appearance for Daryl L. Joseffer as principal counsel for Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 01/13/2017 by email. [399194] [Daryl Joseffer] [Entered: 01/13/2017 05:12 PM] (2) |
| Jan 13, 2017 | 13 | Certificate of Interest for the Appellees Amgen Inc., Amgen Manufacturing Limited and Amgen USA, Inc.. Service: 01/13/2017 by email. [399195] [Daryl Joseffer] [Entered: 01/13/2017 05:13 PM] (2) |
| Jan 13, 2017 | 14 | MOTION of Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC for an emergency stay pending appeal under Rule 8, to expedite briefing schedule. Any response is due within 10 days of service [Consent: opposed]. Service: 01/13/2017 by email. [399220] [Paul Clement] [Entered: 01/13/2017 09:32 PM] (307) |
| Jan 13, 2017 | 15 | Sealed or confidential document received [Exhibit N, Proffer of Dr. Donald Siegel] (corresponding to Doc No. [14]),(corresponding to Doc No. [14]) for Appellants Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi and Sanofi-Aventis U.S., LLC. Service: 01/13/2017 by email. [399221] [Paul Clement] [Entered: 01/13/2017 09:45 PM] (0) |
| Jan 12, 2017 | 1 | Appeal docketed. Received: 01/12/2017. [398362]Entry of Appearance due 01/26/2017. Certificate of Interest is due on 01/26/2017. Docketing Statement due 01/26/2017. Appellant/Petitioner's brief is due 03/13/2017. [JCA] [Entered: 01/12/2017 03:49 PM] (53) |
